Skip to main content

Table 4 Distribution of patients by study centers and according to the final diagnosis and performed diagnostic investigations

From: Diagnosis of celiac disease and applicability of ESPGHAN guidelines in Mediterranean countries: a real life prospective study

Country

N. Pts.

N. CCD +

NCCDa

N. UCD

N. PCD

N. tTG

N. EMA (in CCD)

N. Intestinal biopsy (in CCD)

N. HLA

Albania

45

25

20

0

45

7 (1)

32 (25)

0

Algeria

71

17

54

0

70

6 (2)

54 (17)

0

Croatia

310

12 + 1

293

3

304

25 (6)

202 (12)

14

Egypt

200

5

195

0

159

0

21 (5)

0

Greece

46

35

10

1

46

40 (31)

46 (35)

27

Italy (ME)

332

111

199

15

307

273 (108)

142 (111)

13

Italy (NA)

339

152 + 9

153

17

330

281 (151)

202 (152)

109

Malta

27

14

13

0

26

16 (14)

27 (14)

0

Montenegro

18

11

4

2

17

5 (3)

16 (11)

11

Morocco

106

45

61

0

100

1 (1)

90 (45)

0

Slovenia

234

29 + 1

203

1

234

234 (29)

34 (29)

66

Spain

40

4 + 3

32

1

40

10 (4)

8 (4)

9

Tunisia

67

22

44

1

66

23 (11)

43 (22)

0

Turkey

139

29

109

1

139

5 (1)

85 (29)

133

TOTAL

1974

511 + 14

1391

42

1883

926 (362)

1002 (511)

382

  1. N. Pts Number of Patients, N. CCD Number of Patients with Confirmed Celiac Disease, N. UCD Number of Patients with Unconfirmed Celiac Disease, N. PCD N. of Patients with potential celiac disease, N. tTG Number of tissue TransGlutaminase antibody assays, N. EMA Number of EndoMysial Antibody assays
  2. adiagnosed according to new ESPGHAN criteria omitting biopsy